JP2007522153A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007522153A5 JP2007522153A5 JP2006552438A JP2006552438A JP2007522153A5 JP 2007522153 A5 JP2007522153 A5 JP 2007522153A5 JP 2006552438 A JP2006552438 A JP 2006552438A JP 2006552438 A JP2006552438 A JP 2006552438A JP 2007522153 A5 JP2007522153 A5 JP 2007522153A5
- Authority
- JP
- Japan
- Prior art keywords
- mammal
- hcg
- pharmaceutical composition
- neural stem
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000124008 Mammalia Species 0.000 claims description 22
- 210000001178 neural stem cell Anatomy 0.000 claims description 17
- 102000003951 Erythropoietin Human genes 0.000 claims description 15
- 108090000394 Erythropoietin Proteins 0.000 claims description 15
- 229940105423 erythropoietin Drugs 0.000 claims description 15
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 15
- 230000004770 neurodegeneration Effects 0.000 claims description 11
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 230000004766 neurogenesis Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 210000004556 brain Anatomy 0.000 claims description 4
- 208000029028 brain injury Diseases 0.000 claims description 3
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims 14
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims 14
- 229940084986 human chorionic gonadotropin Drugs 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 102000009151 Luteinizing Hormone Human genes 0.000 claims 8
- 108010073521 Luteinizing Hormone Proteins 0.000 claims 8
- 229940040129 luteinizing hormone Drugs 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 4
- 210000001320 hippocampus Anatomy 0.000 claims 3
- 230000002708 enhancing effect Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 210000004248 oligodendroglia Anatomy 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 239000003016 pheromone Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 3
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 3
- 102000003693 Hedgehog Proteins Human genes 0.000 description 3
- 108090000031 Hedgehog Proteins Proteins 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
- 102000011923 Thyrotropin Human genes 0.000 description 3
- 108010061174 Thyrotropin Proteins 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 3
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 3
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 description 2
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- UFTCZKMBJOPXDM-XXFCQBPRSA-N pituitary adenylate cyclase-activating polypeptide Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 UFTCZKMBJOPXDM-XXFCQBPRSA-N 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 210000004198 anterior pituitary gland Anatomy 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000001153 interneuron Anatomy 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000006764 neuronal dysfunction Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54491504P | 2004-02-13 | 2004-02-13 | |
| US60/544,915 | 2004-02-13 | ||
| PCT/CA2005/000184 WO2005077404A1 (en) | 2004-02-13 | 2005-02-14 | Use of luteinizing hormone (lh) and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007522153A JP2007522153A (ja) | 2007-08-09 |
| JP2007522153A5 true JP2007522153A5 (https=) | 2011-06-02 |
| JP4990634B2 JP4990634B2 (ja) | 2012-08-01 |
Family
ID=34860512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006552438A Expired - Fee Related JP4990634B2 (ja) | 2004-02-13 | 2005-02-14 | 神経幹細胞の増殖および神経発生のための黄体化ホルモン（ＬＨ）、および絨毛性ゴナドトロピン（ｈＣＧ）の使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US7846898B2 (https=) |
| EP (1) | EP1740202B1 (https=) |
| JP (1) | JP4990634B2 (https=) |
| AT (1) | ATE556716T1 (https=) |
| AU (2) | AU2005211847B2 (https=) |
| CA (1) | CA2556266A1 (https=) |
| ES (1) | ES2392282T3 (https=) |
| WO (1) | WO2005077404A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002325712C1 (en) | 2001-08-30 | 2008-07-31 | Stem Cell Therapeutics Inc. | Differentiation of neural stem cells and therapeutic use theeof |
| JP4906231B2 (ja) | 2001-09-14 | 2012-03-28 | ステム セル セラピューティクス インコーポレイテッド | プロラクチン誘導性の神経幹細胞数の増加ならびにその治療用途 |
| WO2003024471A2 (en) * | 2001-09-18 | 2003-03-27 | Stem Cell Therapeutics Inc. | Effect of growth hormone and igf-1 on neural stem cells and therapeutic application |
| WO2004011497A1 (en) * | 2002-07-31 | 2004-02-05 | Stem Cell Therapeutics Inc. | Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap) |
| US20070111932A1 (en) * | 2003-07-31 | 2007-05-17 | Stem Cell Therapeutics Inc. | Method of enhancing and/or inducing neuronal migration using erythropoietin |
| WO2005077404A1 (en) | 2004-02-13 | 2005-08-25 | Stem Cell Therapeutics Corp. | Use of luteinizing hormone (lh) and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis |
| US7534765B2 (en) | 2005-09-27 | 2009-05-19 | Stem Cell Therapeutics Corp. | Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactin |
| KR20080103108A (ko) * | 2006-03-17 | 2008-11-26 | 스템 셀 테라퓨틱스 코포레이션 | 신경 장애 치료를 위한 ｌｈ 또는 ｈｃｇ 및 ｅｐｏ의 투여방법 |
| US8574567B2 (en) | 2007-05-03 | 2013-11-05 | The Brigham And Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
| US20100291042A1 (en) | 2007-05-03 | 2010-11-18 | The Brigham And Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
| WO2012164137A1 (es) | 2011-05-30 | 2012-12-06 | Fundación Investigación En Regeneración Del Sistema Nervioso | Células madre y células de la estirpe neural derivadas de la glía envolvente olfatoria, y sus aplicaciones |
| WO2014179139A2 (en) * | 2013-04-30 | 2014-11-06 | Albert Einstein College Of Medicine Of Yeshiva University | TREATMENT OF AGING EFFECTS BY GONADOTROPIN-RELEASING HORMONE, NEUROGENESIS OR BRAIN IKK-β/NF-κΒ INHIBITION |
| US11439668B2 (en) | 2014-05-23 | 2022-09-13 | JangoBio, LLC | Methods to differentiate stem cells into hormone-producing cells |
| US11253549B2 (en) | 2014-05-23 | 2022-02-22 | JangoBio, LLC | Methods to rebalance the hypothalamic-pituitary-gonadal axis |
| WO2022187359A1 (en) * | 2021-03-02 | 2022-09-09 | Wisconsin Alumni Research Foundation | Methods of treating hypogonadotropic hypogonadism and cognition impairment following a traumatic brain injury |
Family Cites Families (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4840896A (en) | 1983-11-02 | 1989-06-20 | Integrated Genetics, Inc. | Heteropolymeric protein |
| NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| KR850004274A (ko) * | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
| US4703008A (en) * | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
| US4902680A (en) * | 1984-10-29 | 1990-02-20 | Chaovanee Aroonsakul | Treating central nervous system diseases |
| US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4801575A (en) | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| JPH01180833A (ja) | 1988-01-11 | 1989-07-18 | Nippon Kayaku Co Ltd | 血管新生剤 |
| EP0397834B1 (en) * | 1988-10-28 | 2000-02-02 | Genentech, Inc. | Method for identifying active domains and amino acid residues in polypeptides and hormone variants |
| EP0441889A1 (fr) | 1988-11-07 | 1991-08-21 | Commission des Communautés Européennes | Hormone de croissance humaine modifiee |
| US5128242A (en) | 1989-06-19 | 1992-07-07 | The Administrators Of The Tulane Educational Fund | Hypothalamic polypeptides with adenylate cyclase stimulating activity |
| US5198542A (en) | 1989-06-20 | 1993-03-30 | Takeda Chemical Industries, Inc. | Dna encoding a pitvitary adenylate cyclase activating protein and use thereof |
| US5527527A (en) * | 1989-09-07 | 1996-06-18 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
| US6329508B1 (en) * | 1989-09-07 | 2001-12-11 | Alkermes, Inc. | Transferrin receptor reactive chimeric antibodies |
| US5977307A (en) * | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
| US5268164A (en) * | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| EP0467279A3 (en) | 1990-07-18 | 1992-08-05 | Takeda Chemical Industries, Ltd. | Polypeptides having c-amp producing activity |
| US5521069A (en) | 1990-08-10 | 1996-05-28 | Takeda Chemical Industries, Ltd. | Genomic DNA exons having exons encoding human pituitary adenylate cyclase activity peptide with 38 amino acids residues(PACAP38) and a promoter thereof |
| US5189179A (en) * | 1990-08-29 | 1993-02-23 | Merrell Dow Pharmaceuticals Inc. | Serotonin 5ht1a agonists |
| US5231178A (en) | 1991-01-16 | 1993-07-27 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Method for the purification of intact, correctly-folded insulin-like growth factor-1 |
| US5723115A (en) * | 1991-05-02 | 1998-03-03 | W. Alton Jones Cell Science Center, Inc. | Inhibition of adipose tissue development and obesity |
| US5767215A (en) | 1991-05-09 | 1998-06-16 | Borealis Holding A/S | Coarse-grained polyolefin, its production method and a catalyst used in the method |
| US6429186B1 (en) * | 1991-05-10 | 2002-08-06 | Genentech, Inc. | Ligand antagonists for treatment of breast cancer |
| JP3417558B2 (ja) * | 1991-05-10 | 2003-06-16 | ジェネンテク，インコーポレイテッド | 配位子作用薬および拮抗薬の選択 |
| ES2198404T5 (es) | 1991-07-08 | 2008-05-01 | Neurospheres Holdings Ltd. | Celulas progenitoras neurales que responden a factor de crecimiento y que se pueden hacer proliferar in vitro. |
| US5750376A (en) * | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
| US6294346B1 (en) * | 1991-07-08 | 2001-09-25 | Neurospheres Holdings, Ltd. | Use of multipotent neural stem cells and their progeny for the screening of drugs and other biological agents |
| US5980885A (en) * | 1991-07-08 | 1999-11-09 | Neurospheres Holdings Ltd. | Growth factor-induced proliferation of neural precursor cells in vivo |
| US5851832A (en) * | 1991-07-08 | 1998-12-22 | Neurospheres, Ltd. | In vitro growth and proliferation of multipotent neural stem cells and their progeny |
| AU2489992A (en) * | 1991-08-16 | 1993-03-16 | Chiron Corporation | Muteins of epidermal growth factor exhibiting enhanced binding at low ph |
| US5623050A (en) * | 1991-08-22 | 1997-04-22 | Takeda Chemical Industries, Ltd. | Stable polypeptides having c-AMP production enhancing activity and the use thereof |
| US5253648A (en) * | 1991-10-11 | 1993-10-19 | Spacelabs Medical, Inc. | Method and apparatus for excluding artifacts from automatic blood pressure measurements |
| US5239105A (en) * | 1992-01-30 | 1993-08-24 | The Dow Chemical Company | Catalytic formation of diarylcarbonates |
| JPH07508025A (ja) | 1992-05-08 | 1995-09-07 | トーマス・ジェファーソン・ユニバーシティ | インスリン様増殖因子（ｉｇｆ−１）類似体 |
| US5614184A (en) * | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
| AU683023B2 (en) | 1992-10-16 | 1997-10-30 | Neurospheres Holdings Ltd | Remyelination using neural stem cells |
| EP0669973B9 (en) | 1992-10-28 | 2007-10-10 | NeuroSpheres Holdings Ltd. | Biological factors and neural stem cells |
| US5877169A (en) * | 1993-11-05 | 1999-03-02 | University Of Florida Research Foundation, Inc. | Methods of treatment of ischemic damage |
| CA2175992C (en) | 1993-11-09 | 2008-04-01 | Samuel Weiss | In situ modification and manipulation of stem cells of the central nervous system |
| US5773569A (en) * | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
| US6399316B1 (en) | 1994-02-25 | 2002-06-04 | Takeda Chemical Industries, Ltd. | PACAP receptor protein, method for preparing said protein, and use thereof |
| US6551618B2 (en) | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
| US6239105B1 (en) | 1994-03-31 | 2001-05-29 | Barbara A. Brewitt | Homeopathic preparations of purified growth hormone |
| WO1995029690A1 (en) * | 1994-04-29 | 1995-11-09 | The Trustees Of The University Of Pennsylvania | Biologically active peptides and methods of identifying the same |
| US5840576A (en) | 1994-07-20 | 1998-11-24 | Cytotherapeutics, Inc. | Methods and compositions of growth control for cells encapsulated within bioartificial organs |
| US5885574A (en) * | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
| US6680295B1 (en) | 1994-09-22 | 2004-01-20 | The Administrators Of The Tulane Educational Fund | Method and pharmaceutical composition for prevention and treatment of brain damage |
| JPH10505863A (ja) | 1994-09-22 | 1998-06-09 | ジ・アドミニストレーターズ・オブ・ザ・チューレン・エデュケイショナル・ファンド | 脳障害の予防および治療のための方法および医薬組成物 |
| FI971956L (fi) | 1994-11-14 | 1997-07-04 | Neurospheres Holdings Ltd | Hermosolujen lisääntymisen säännöstely |
| US6015555A (en) * | 1995-05-19 | 2000-01-18 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
| AU6163196A (en) | 1995-06-07 | 1996-12-30 | Smithkline Beecham Corporation | Method for obtaining receptor agonist antibodies |
| US5547993A (en) * | 1995-10-24 | 1996-08-20 | Mitsubishi Chemical Corporation | Therapeutic agent for glaucoma |
| US6346390B1 (en) * | 1996-03-08 | 2002-02-12 | Receptron, Inc. | Receptor derived peptides involved in modulation of response to ligand binding |
| US6017533A (en) | 1996-04-25 | 2000-01-25 | Shiseido Company, Ltd. | Peptides having specific affinity to pituitary adenylate cyclase activating polypeptide type 1 receptors |
| US5753506A (en) * | 1996-05-23 | 1998-05-19 | Cns Stem Cell Technology, Inc. | Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals |
| AU3492497A (en) | 1996-06-21 | 1998-01-07 | Arris Pharmaceutical Corporation | Bivalent molecules that form an activating complex with an erythropoietin receptor |
| IT1284876B1 (it) | 1996-08-07 | 1998-05-22 | Applied Research Systems | Hcg come inibitore della collagenasi |
| US6583109B1 (en) | 1997-06-24 | 2003-06-24 | Robert C. Gallo | Therapeutic polypeptides from β-hCG and derivatives |
| CA2301693A1 (en) | 1997-09-19 | 1999-04-01 | Klaus Unsicker | Cytokines having neurotrophic activity |
| US6165783A (en) | 1997-10-24 | 2000-12-26 | Neuro Spheres Holdings Ltd. | Erythropoietin-mediated neurogenesis |
| CA2308135A1 (en) * | 1997-10-31 | 1999-05-14 | John G. Gleason | Novel metal complexes |
| TW445295B (en) * | 1997-12-31 | 2001-07-11 | Shiu Li Wei | Expression vector pcDNA3.1-HC for human erythropoietin, BHK-21 host cell line transformed therewith, and production of human erythropoietin using the transformed cell |
| US6812027B2 (en) | 1998-03-25 | 2004-11-02 | Cornell Research Foundation, Inc. | Discovery, localization, harvest, and propagation of an FGF2 and BDNF-responsive population of neural and neuronal progenitor cells in the adult human forebrain |
| US6242563B1 (en) * | 1998-07-20 | 2001-06-05 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Peptide analogues |
| HUP0104934A3 (en) | 1998-07-20 | 2002-05-28 | Sod Conseils Rech Applic | Peptide analogues of pacap, pharmaceutical compositions comprising thereof and their use |
| CN1261158C (zh) | 1998-09-03 | 2006-06-28 | 诺兰兹公司 | 生长激素在制备用于诱导神经保护作用的药剂中的应用 |
| SE9804064D0 (sv) | 1998-11-25 | 1998-11-25 | A & Science Invest Ab | Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells |
| DE19857609A1 (de) * | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
| FR2794473B1 (fr) | 1999-06-03 | 2003-09-26 | Centre Nat Rech Scient | Procede de multiplication de cellules souches |
| US6618698B1 (en) * | 1999-08-12 | 2003-09-09 | Quickturn Design Systems, Inc. | Clustered processors in an emulation engine |
| AU2118501A (en) | 1999-10-20 | 2001-04-30 | Stemcells, Inc. | Methods for inducing in vivo proliferation and migration of transplanted progenitor cells in the brain |
| US6395546B1 (en) | 2000-02-01 | 2002-05-28 | Neurogeneration, Inc. | Generation of dopaminergic neurons from human nervous system stem cells |
| KR100358754B1 (ko) | 2000-02-14 | 2002-11-07 | 대한민국 | 인간의 조혈촉진제 생산을 위한 형질전환 돼지를 생산하는방법 및 그 형질전환 돼지 |
| US7259146B2 (en) * | 2000-05-26 | 2007-08-21 | Ortho-Mcneil Pharmaceutical, Inc. | Neuroprotective peptides |
| AU7107301A (en) | 2000-07-18 | 2002-01-30 | Nichimo Co. Ltd. | Stem cell reinforcing material |
| US7547674B2 (en) | 2001-06-06 | 2009-06-16 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
| IL156828A0 (en) | 2001-01-12 | 2004-02-08 | Waratah Pharmaceuticals Inc | Prolonged efficacy of islet neogenesis therapy methods with a gastrin/cck receptor ligand and an egf receptor ligand composition in subjects with preexisting diabetes |
| EP1390053A2 (en) * | 2001-04-25 | 2004-02-25 | Hernan F. Acevedo | Hcg formulation |
| US6740163B1 (en) | 2001-06-15 | 2004-05-25 | Seagate Technology Llc | Photoresist recirculation and viscosity control for dip coating applications |
| US7132287B2 (en) | 2001-06-18 | 2006-11-07 | Psychiatric Genomics, Inc. | Method for neural stem cell differentiation using 5HT-1A agonists |
| CA2364095C (en) | 2001-07-20 | 2011-07-12 | Neurostasis, Inc | Production of radial glial cells |
| AU2002325712C1 (en) * | 2001-08-30 | 2008-07-31 | Stem Cell Therapeutics Inc. | Differentiation of neural stem cells and therapeutic use theeof |
| JP4906231B2 (ja) | 2001-09-14 | 2012-03-28 | ステム セル セラピューティクス インコーポレイテッド | プロラクチン誘導性の神経幹細胞数の増加ならびにその治療用途 |
| WO2003024471A2 (en) | 2001-09-18 | 2003-03-27 | Stem Cell Therapeutics Inc. | Effect of growth hormone and igf-1 on neural stem cells and therapeutic application |
| US7037504B2 (en) | 2001-10-23 | 2006-05-02 | Waratah Pharmaceuticals, Inc. | Epidermal growth factor protein and gene, and methods of use therefor |
| ITPR20010072A1 (it) | 2001-10-26 | 2003-04-26 | Firaco Srl | Apparato e procedimento di sicurezza per veicoli di trasporto, in particolare aeromobili. |
| US20030144203A1 (en) * | 2001-12-19 | 2003-07-31 | Voyager Pharmaceutical Corporation | Methods for slowing senescence and treating and preventing diseases associated with senescence |
| AU2003228050A1 (en) | 2002-05-03 | 2003-11-17 | Neuronova Ab | Therapeutic use of PACAP, Maxadilan, PACAP receptor agonist and/or ADCYAP1R1 in the treatment of CNS disorders |
| AU2003250697B2 (en) | 2002-07-30 | 2008-05-01 | Stem Cell Therapeutics Inc. | Oligodendrocyte production from multipotent neural stem cells |
| WO2004011021A1 (en) | 2002-07-31 | 2004-02-05 | Stem Cell Therapeutics Inc. | Method of enhancing and/or inducing neuronal migration using erythropoietin |
| WO2004011497A1 (en) | 2002-07-31 | 2004-02-05 | Stem Cell Therapeutics Inc. | Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap) |
| DE60335743D1 (de) * | 2002-11-20 | 2011-02-24 | Neuronova Ab | Verbindungen und verfahren zur erhöhung der neurogenese |
| NZ542092A (en) * | 2003-03-27 | 2008-04-30 | Janssen Pharmaceutica Nv | Use of erythropoietin (EPO) in stroke recovery wherein the EPO is formulated for administration for a particular dosage regime |
| US20070111932A1 (en) | 2003-07-31 | 2007-05-17 | Stem Cell Therapeutics Inc. | Method of enhancing and/or inducing neuronal migration using erythropoietin |
| WO2005077404A1 (en) | 2004-02-13 | 2005-08-25 | Stem Cell Therapeutics Corp. | Use of luteinizing hormone (lh) and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis |
| CA2582567A1 (en) | 2004-10-07 | 2006-04-13 | Stem Cell Therapeutics Corp. | Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds |
| US7534765B2 (en) | 2005-09-27 | 2009-05-19 | Stem Cell Therapeutics Corp. | Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactin |
| KR20080103108A (ko) | 2006-03-17 | 2008-11-26 | 스템 셀 테라퓨틱스 코포레이션 | 신경 장애 치료를 위한 ｌｈ 또는 ｈｃｇ 및 ｅｐｏ의 투여방법 |
| WO2008077027A2 (en) * | 2006-12-18 | 2008-06-26 | Case Western Reserve University | Treatment of post-menopausal and post-hysterectomy mediated cognitive disorders |
| US20100028361A1 (en) * | 2006-12-19 | 2010-02-04 | Smith Mark A | Brain-derived gonadotropins and cognition |
| US20080286234A1 (en) * | 2007-05-15 | 2008-11-20 | Eyink Daniel A | Method for treating demyelinating diseases |
| EP2217252A2 (en) | 2007-10-29 | 2010-08-18 | Hadasit Medical Research Services & Development Limited | Human stem cell-derived neural precursors for treatment of autoimmune diseases of the central nervous system |
| AU2009246047A1 (en) | 2008-05-13 | 2009-11-19 | The University Of Queensland | Method of inducing proliferation and/or differentiation of neural precursor cells by introducing prolactin or Wnt3a to activate latent neural precursor cells |
-
2005
- 2005-02-14 WO PCT/CA2005/000184 patent/WO2005077404A1/en not_active Ceased
- 2005-02-14 JP JP2006552438A patent/JP4990634B2/ja not_active Expired - Fee Related
- 2005-02-14 CA CA002556266A patent/CA2556266A1/en not_active Abandoned
- 2005-02-14 US US11/058,441 patent/US7846898B2/en not_active Expired - Fee Related
- 2005-02-14 ES ES05706487T patent/ES2392282T3/es not_active Expired - Lifetime
- 2005-02-14 EP EP05706487A patent/EP1740202B1/en not_active Expired - Lifetime
- 2005-02-14 AU AU2005211847A patent/AU2005211847B2/en not_active Ceased
- 2005-02-14 AT AT05706487T patent/ATE556716T1/de active
-
2010
- 2010-10-29 US US12/915,713 patent/US8217002B2/en not_active Expired - Fee Related
-
2011
- 2011-05-24 AU AU2011202404A patent/AU2011202404A1/en not_active Abandoned
-
2012
- 2012-06-11 US US13/493,514 patent/US8435949B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007522153A5 (https=) | ||
| Danesh-Meyer | Neuroprotection in glaucoma: recent and future directions | |
| Mitchell et al. | Invited Review: Neuroplasticity in respiratory motor control | |
| Wegerer et al. | Persistently increased density of serotonin transporters in the frontal cortex of rats treated with fluoxetine during early juvenile life | |
| Nickl-Jockschat et al. | The role of neurotrophic factors in autism | |
| Fernandez-Sanchez et al. | Controlled delivery of tauroursodeoxycholic acid from biodegradable microspheres slows retinal degeneration and vision loss in P23H rats | |
| Naskar et al. | New horizons in neuroprotection | |
| Gu et al. | Recombinant human NGF-loaded microspheres promote survival of basal forebrain cholinergic neurons and improve memory impairments of spatial learning in the rat model of Alzheimer's disease with fimbria-fornix lesion | |
| Ducray et al. | GDNF family ligands display distinct action profiles on cultured GABAergic and serotonergic neurons of rat ventral mesencephalon | |
| PT2200621E (pt) | Métodos, composições farmacêuticas e artigos de fabrico para administrar células terapêuticas no sistema nervoso central do animal | |
| Cerri et al. | Conjunctivally applied BDNF protects photoreceptors from light-induced damage | |
| Babai et al. | Degree of damage compensation by various PACAP treatments in monosodium glutamate-induced retinal degeneration | |
| ES2656353T3 (es) | Nuevas aplicaciones de HIP/PAP o derivados de la misma | |
| DE69522578T2 (de) | Glial neurotropher faktor als nervenschutzmittel | |
| Zeng et al. | Small molecules activating TrkB receptor for treating a variety of CNS disorders | |
| Krout et al. | CNS neurons with links to both mood-related cortex and sympathetic nervous system | |
| US9987329B2 (en) | Methods for treating peripheral nerve damage | |
| Huang et al. | The macroscopic and microscopic effect of low-frequency whole-body vibration after cerebral ischemia in rats | |
| Koo et al. | Expression of glial cell line-derived neurotrophic factor (GDNF) in the developing human fetal brain | |
| IT201600112420A1 (it) | Nuova formulazione per via intranasale | |
| DK2501362T3 (en) | Ophthalmic compositions are based on BDNF (Brain-Derived Neurotrophic Factor), and use thereof | |
| NO940084L (no) | Fremgangsmåte for behandling av motor-neuron sykdommer ved anvendelse av medlemmer av BDNF/NT-3/NGF familien av molekyler | |
| Tirassa | The nerve growth factor administrated as eye drops activates mature and precursor cells in subventricular zone of adult rats | |
| US20140315811A1 (en) | Ophthalmic preparations based on pacap (pituitary adenylate cyclase activating polypeptide) which restore the normal visual function in early glaucoma | |
| Xiao et al. | Neuroprotection of retinal ganglion cells with GDNF-Loaded biodegradable microspheres in experimental glaucoma |